Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
151 hedge funds and large institutions have $704M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2021 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 49 increasing their positions, 49 reducing their positions, and 62 closing their positions.
38% more call options, than puts
Call options by funds: $18.7M | Put options by funds: $13.6M
0% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 49
17% less funds holding
Funds holding: 181 → 151 (-30)
45% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 62
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
74% less capital invested
Capital invested by funds: $2.69B → $704M (-$1.98B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$77.8M |
| 2 |
Millennium Management
New York
|
+$46.8M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$25.5M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$25M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$20.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$89.6M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$68.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.4M |
| 4 |
DFO
Duquesne Family Office
New York
|
-$22.3M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$15.8M |
RETA Hedge Fund Activity: Q4 2021 in Review
151 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q4 2021, worth a combined $704M — down 74% from $2.69B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of RETA and 34 opened new positions — a net loss of 28 holders — while 49 trimmed existing stakes and 49 added.
The largest buyer was Goldman Sachs, adding an estimated $77.8M. The largest seller was Invesco, cutting an estimated $89.6M.
- 151 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q4 2021, down from 181 in Q3 2021.
- Funds reported $704M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q4 2021, down 74% quarter-over-quarter.
- 34 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q4 2021 and 62 closed out, a net change of -28 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q4 2021 was Goldman Sachs, an estimated $77.8M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q4 2021 was Invesco, an estimated $89.6M sold.
Based on aggregated 13F filings for Q4 2021.